London’s Unravel Health Secures €2.96 Million for Hormone Tracking Device

How the Micro Lab Works

Unravel Health, a London-based startup, has raised €2.96 million to develop a palm-sized device that measures hormones from saliva at home. The funding round, led by Conduit EIS Impact Fund and Wrightwood, includes participation from Leo Capital, Embryo Ventures, and Herme. The company aims to launch the Micro Lab, which delivers results in minutes, to help women monitor hormonal changes daily.

The Micro Lab analyzes saliva samples to detect multiple hormones quickly. Users collect a sample, insert it into the device, and receive readings within minutes. This eliminates the need for lab visits and waiting days for results. The technology targets hormones linked to menstrual cycles, fertility, and menopause. Early testing shows accuracy comparable to clinical methods. The device is designed for repeated use over time.

Can Daily Hormone Tracking Improve Women’s Health?

Unravel Health believes frequent monitoring can reveal patterns missed by occasional tests. By tracking shifts in real time, users may identify issues like imbalances or ovulation windows sooner. This could support better decisions around contraception, conception, or symptom management. The startup plans to pair the device with an app for trend analysis. Long-term data might also aid research into conditions like PCOS or endometriosis. Regulatory approval is the next major step before market launch.

What hormones can the Micro Lab detect? The device is designed to measure key hormones such as estrogen, progesterone, and cortisol from saliva samples, with plans to expand the panel based on user needs and clinical relevance.

Frequently Asked Questions

Is the device reusable? Yes, the Micro Lab is built for multiple uses, with replaceable components for sample processing while the main reader remains durable over time.

When will the product be available? Unravel Health aims to complete development and regulatory steps within the next 18 to 24 months, targeting a launch in select European markets first.